{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:29:09Z","timestamp":1773901749793,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s12325-023-02631-w","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T11:01:49Z","timestamp":1692702109000},"page":"4777-4791","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Impact of Sodium Zirconium Cyclosilicate Plus Renin\u2013Angiotensin\u2013Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE\u00a0II Real-World Study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8402-8961","authenticated-orcid":false,"given":"Jamie P.","family":"Dwyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2369-8507","authenticated-orcid":false,"given":"Abiy","family":"Agiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7355-8123","authenticated-orcid":false,"given":"Yemisi","family":"Oluwatosin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,22]]},"reference":[{"issue":"5","key":"2631_CR1","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie X, Liu Y, Perkovic V, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67(5):728\u201341.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"2631_CR2","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type\u00a02 diabetes and nephropathy. N Engl J Med. 2001;345(12):861\u20139.","journal-title":"N Engl J Med"},{"issue":"20","key":"2631_CR3","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329(20):1456\u201362.","journal-title":"N Engl J Med"},{"issue":"12","key":"2631_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type\u00a02 diabetes. N Engl J Med. 2001;345(12):851\u201360.","journal-title":"N Engl J Med"},{"issue":"2","key":"2631_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","volume":"135","author":"TH Jafar","year":"2001","unstructured":"Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med. 2001;135(2):73\u201387.","journal-title":"Ann Intern Med"},{"issue":"18","key":"2631_CR6","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895\u20131032.","journal-title":"Circulation"},{"key":"2631_CR7","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3):S1\u2013S87.","DOI":"10.1016\/j.kint.2020.11.003"},{"issue":"3","key":"2631_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","volume":"4","author":"GMC Rosano","year":"2018","unstructured":"Rosano GMC, Tamargo J, Kjeldsen KP, et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother. 2018;4(3):180\u20138.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"7","key":"2631_CR9","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005428","volume":"6","author":"G Bandak","year":"2017","unstructured":"Bandak G, Sang Y, Gasparini A, et al. Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm CREAtinine Measurements (SCREAM) project. J Am Heart Assoc. 2017;6(7):e005428.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2631_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.kisu.2017.09.001","volume":"7","author":"L Fried","year":"2017","unstructured":"Fried L, Kovesdy CP, Palmer BF. New options for the management of chronic hyperkalemia. Kidney Int Suppl (2011). 2017;7(3):164\u201370.","journal-title":"Kidney Int Suppl (2011)"},{"issue":"6","key":"2631_CR11","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1080\/03007995.2018.1433141","volume":"34","author":"KA Betts","year":"2018","unstructured":"Betts KA, Woolley JM, Mu F, McDonald E, Tang W, Wu EQ. The prevalence of hyperkalemia in the United States. Curr Med Res Opin. 2018;34(6):971\u20138.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"2631_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000479802","volume":"46","author":"AJ Collins","year":"2017","unstructured":"Collins AJ, Pitt B, Reaven N, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes. Am J Nephrol. 2017;46(3):213\u201321.","journal-title":"Am J Nephrol"},{"key":"2631_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ijcard.2017.07.035","volume":"245","author":"E Nilsson","year":"2017","unstructured":"Nilsson E, Gasparini A, Arnlov J, et al. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system. Int J Cardiol. 2017;245:277\u201384.","journal-title":"Int J Cardiol"},{"issue":"11","key":"2631_CR14","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1681\/ASN.2016121344","volume":"28","author":"JR Montford","year":"2017","unstructured":"Montford JR, Linas S. How dangerous is hyperkalemia? J Am Soc Nephrol. 2017;28(11):3155\u201365.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2631_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ekir.2017.11.003","volume":"3","author":"KA Betts","year":"2018","unstructured":"Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Wu EQ. The cost of hyperkalemia in the United States. Kidney Int Rep. 2018;3(2):385\u201393.","journal-title":"Kidney Int Rep"},{"issue":"7","key":"2631_CR16","first-page":"352","volume":"12","author":"NR Desai","year":"2019","unstructured":"Desai NR, Reed P, Alvarez PJ, Fogli J, Woods SD, Owens MK. The economic implications of hyperkalemia in a Medicaid managed care population. Am Health Drug Benefits. 2019;12(7):352\u201361.","journal-title":"Am Health Drug Benefits"},{"issue":"8","key":"2631_CR17","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.ekir.2020.06.004","volume":"5","author":"KA Betts","year":"2020","unstructured":"Betts KA, Woolley JM, Mu F, et al. Postdischarge health care costs and readmission in patients with hyperkalemia-related hospitalizations. Kidney Int Rep. 2020;5(8):1280\u201390.","journal-title":"Kidney Int Rep"},{"issue":"4","key":"2631_CR18","first-page":"202","volume":"10","author":"K Fitch","year":"2017","unstructured":"Fitch K, Woolley JM, Engel T, Blumen H. The clinical and economic burden of hyperkalemia on Medicare and commercial payers. Am Health Drug Benefits. 2017;10(4):202\u201310.","journal-title":"Am Health Drug Benefits"},{"issue":"8","key":"2631_CR19","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1080\/03007995.2020.1775072","volume":"36","author":"F Mu","year":"2020","unstructured":"Mu F, Betts KA, Woolley JM, et al. Prevalence and economic burden of hyperkalemia in the United States Medicare population. Curr Med Res Opin. 2020;36(8):1333\u201341.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2631_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/jphsr\/rmaa004","volume":"12","author":"A Sharma","year":"2021","unstructured":"Sharma A, Alvarez PJ, Woods SD, Fogli J, Dai D. Healthcare resource utilization and costs associated with hyperkalemia in a large managed care population. J Pharm Health Serv Res. 2021;12(1):35\u201341.","journal-title":"J Pharm Health Serv Res"},{"issue":"2","key":"2631_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/14737167.2023.2161514","volume":"23","author":"CV Pollack Jr","year":"2023","unstructured":"Pollack CV Jr, Agiro A, Mu F, et al. Impact on hospitalizations of long-term versus short-term therapy with sodium zirconium cyclosilicate during routine outpatient care of patients with hyperkalemia: the RECOGNIZE I study. Expert Rev Pharmacoecon Outcomes Res. 2023;23(2):241\u201350.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"2631_CR22","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.mayocp.2020.06.014","volume":"96","author":"BF Palmer","year":"2021","unstructured":"Palmer BF, Carrero JJ, Clegg DJ, et al. Clinical management of hyperkalemia. Mayo Clin Proc. 2021;96(3):744\u201362.","journal-title":"Mayo Clin Proc"},{"issue":"23","key":"2631_CR23","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.3390\/jcm10235483","volume":"10","author":"A Montagnani","year":"2021","unstructured":"Montagnani A, Frasson S, Gussoni G, Manfellotto D. Optimization of RAASi therapy with new potassium binders for patients with heart failure and hyperkalemia: rapid review and meta-analysis. J Clin Med. 2021;10(23):5483.","journal-title":"J Clin Med"},{"issue":"6","key":"2631_CR24","doi-asserted-by":"publisher","first-page":"798","DOI":"10.2215\/CJN.12651018","volume":"14","author":"BS Spinowitz","year":"2019","unstructured":"Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia. Clin J Am Soc Nephrol. 2019;14(6):798\u2013809.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2631_CR25","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1007\/s12325-023-02518-w","volume":"40","author":"A Agiro","year":"2023","unstructured":"Agiro A, Amin AN, Cook EE, et al. Real-world modifications of renin-angiotensin-aldosterone system inhibitors in patients with hyperkalemia initiating sodium zirconium cyclosilicate therapy: the OPTIMIZE\u00a0I study. Adv Ther. 2023;40(6):2886\u2013901.","journal-title":"Adv Ther"},{"key":"2631_CR26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1681\/ASN.20213210S17d","volume":"32","author":"SG Coca","year":"2021","unstructured":"Coca SG, Rowan CG, Alvarez PJ, Golestaneh L, Desai N. Comparative effectiveness of patiromer and RAAS inhibitor continuation vs. no potassium binder and discontinued RAAS inhibitors on healthcare resource utilization and cost outcomes in hyperkalemia [abstract]. J Am Soc Nephrol. 2021;32:7\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"4-a","key":"2631_CR27","first-page":"S2","volume":"23","author":"M Polson","year":"2017","unstructured":"Polson M, Lord TC, Kangethe A, et al. Clinical and economic impact of hyperkalemia in patients with chronic kidney disease and heart failure. J Manag Care Spec Pharm. 2017;23(4-a):S2\u20139.","journal-title":"J Manag Care Spec Pharm"},{"key":"2631_CR28","unstructured":"Clinicaltrials.gov. Study to assess efficacy and safety of SZC for the management of high potassium in patients with symptomatic HFrEF receiving spironolactone (REALIZE-K). 2020. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04676646. Accessed July 19, 2023."},{"issue":"2","key":"2631_CR29","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/ehf2.14268","volume":"10","author":"J-C Tardif","year":"2023","unstructured":"Tardif J-C, Rouleau J, Chertow GM, et al. Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure. ESC Heart Fail. 2023;10(2):1066\u201376.","journal-title":"ESC Heart Fail"},{"issue":"4","key":"2631_CR30","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.amjms.2022.04.029","volume":"364","author":"A Amin","year":"2022","unstructured":"Amin A, Moon R, Agiro A, et al. In-hospital mortality, length of stay, and hospitalization cost of COVID-19 patients with and without hyperkalemia. Am J Med Sci. 2022;364(4):444\u201353.","journal-title":"Am J Med Sci"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02631-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02631-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02631-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T15:13:56Z","timestamp":1729955636000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02631-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2631"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02631-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,22]]},"assertion":[{"value":"28 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}